These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 9278467)

  • 1. Low-molecular-weight heparins.
    Weitz JI
    N Engl J Med; 1997 Sep; 337(10):688-98. PubMed ID: 9278467
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
    Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
    Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
    Raskob GE
    Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.
    Kakkar VV
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):9-19. PubMed ID: 9399405
    [No Abstract]   [Full Text] [Related]  

  • 5. New heparin is no heavyweight.
    Feinberg AW
    Health News; 2000 Aug; 6(8):5-6. PubMed ID: 10948870
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and potential uses of low molecular weight heparin: a review and an economic analysis.
    Seo P; Locke CF
    Am J Manag Care; 2000 Apr; 6(4):498-506; quiz 507-8. PubMed ID: 10977456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
    Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
    Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low molecular weight heparins].
    Schröder F; Weiss T
    Dtsch Med Wochenschr; 2002 Aug; 127(31-32):1645-7. PubMed ID: 12168158
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
    Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
    Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme.
    Hull RD; Pineo GF
    Int Angiol; 1998 Sep; 17(3):131-4. PubMed ID: 9821024
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular weight heparin as prophylaxis against thromboembolism after total hip replacement--is it worth the price?
    Persson BM
    Acta Orthop Scand; 2000 Apr; 71(2):215-6. PubMed ID: 10852334
    [No Abstract]   [Full Text] [Related]  

  • 16. [Low molecular weight heparins: mechanisms of action and pharmococynetics. Clinical advantages over the classic unfractioned heparins].
    Campos M
    Rev Port Cir Cardiotorac Vasc; 2003; 10(2):61-7. PubMed ID: 15094887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?
    Dahl OE; Bergqvist D; Cohen AT; Frostick SP; Hull RD
    Acta Orthop Scand; 2001 Apr; 72(2):199-204. PubMed ID: 11372955
    [No Abstract]   [Full Text] [Related]  

  • 19. Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism.
    Edwards JL
    JAMA; 2007 Jan; 297(3):262; author reply 263. PubMed ID: 17227973
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prophylaxis of venous thrombosis, yes but...].
    Korin JD; Sánchez Avalos JC
    Medicina (B Aires); 1996; 56(3):299-307. PubMed ID: 9035489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.